iM4TB awarded USD 2.45 m for anti-TB drug clinical trials

Posted on by in PBTZ169 | Leave a comment

The Bill & Melinda Gates foundation has awarded EPFL-based non-profit iM4TB USD 2.45 million to take their innovative anti-tuberculosis drug PBTZ169 into clinical trials.

Read more here

Comments are closed.